Evi1 forms a bridge between the epigenetic machinery and signaling pathways

Akihide Yoshimi; Mineo Kurokawa

doi:10.18632/oncotarget.304

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Evi1 forms a bridge between the epigenetic machinery and signaling pathways

Akihide Yoshimi _ and Mineo Kurokawa

PDF | HTML | How to cite

Oncotarget. 2011; 2:575-586. https://doi.org/10.18632/oncotarget.304

Metrics: PDF 3712 views | HTML 5137 views | ?

Abstract

Akihide Yoshimi and Mineo Kurokawa

¹Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Received: July 5, 2011; Accepted: July 21, 2011; Published: July 26, 2011;

Keywords: Evi1, Leukemia, Polycomb, PTEN, Rapamycin

Correspondence:

Dr. Mineo Kurokawa, email:

Abstract

Recent studies have demonstrated the significance of the leukemia oncogene Evi1 as the regulator of hematopoietic stem cells and marker of poor clinical outcomes in myeloid malignancies. Evi1-mediated leukemogenic activities include a wide array of functions such as the induction of epigenetic modifications, transcriptional control, and regulation of signaling pathways. We have recently succeeded in comprehensively elucidating the oncogenic function of Evi1 in a model of the polycomb-Evi1-PTEN/AKT/mTOR axis. These results may provide us with novel therapeutic approaches to conquer the poor prognosis associated with Evi1-activated leukemia or other solid tumors with high Evi1 expression. Here, we review the current understanding of the role of Evi1 in controlling the development of leukemia and highlight potential modalities for targeting factors involved in Evi1-regulated signaling.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 304

Publication Alerts

Research Perspectives:

Evi1 forms a bridge between the epigenetic machinery and signaling pathways

Abstract